Stockreport

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equiva [Read more]